Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

LncRNA-ATB inhibits the proliferation and invasion of NSCLC cells by regulating MiR-200s expression

Liping Song¹, Can Zhao¹, Yujiao Zhou¹, Tao Lei¹, Jianguang Cao¹, Min Zhu²

¹Department of Respiratory and Critical Care Medicine, Peking University Shougang Hospital, China; ²Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China.

For correspondence:- Min Zhu Email: 15910956698@163.com Tel:+8613311046698

Accepted: 25 September 2022 Published: 28 October 2022

Citation: Song L, Zhao C, Zhou Y, Lei T, Cao J, Zhu M. LncRNA-ATB inhibits the proliferation and invasion of NSCLC cells by regulating MiR-200s expression. Trop J Pharm Res 2022; 21(10):2049-2055 doi: 10.4314/tjpr.v21i10.2

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of lncRNA-ATB on the proliferation and invasion of non-small cell lung cancer (NSCLC) cells, and its mechanism of action.

Methods: LncRNA-ATB mRNA levels in carcinoma tissues and normal adjacent tissues of 38 NSCLC patients in Peking University Shougang Hospital were determined by reverse transcription-polymerase chain reaction (RT-PCR). Human NSCLC A549 cell line was divided into control and lncRNA-ATB inhibition (si-ATB) groups, respectively. The proliferation and invasion of cells in each group were assessed. Subsequently, the effect of lncRNA-ATB inhibition on the growth of NSCLC cells was evaluated by subcutaneous tumor formation assay.

Results: The expression of lncRNA-ATB was significantly higher in carcinoma tissues than in normal adjacent tissues in NSCLC patients. Cell counting kit-8 (CCK-8) assay results showed that si-ATB group displayed a weakened ability of the cells to proliferate (p < 0.05). Furthermore, deoxyribonucleic acid (DNA) replication ability was weaker in si-ATB group than in the control group. Wound healing assay results showed that the migration ability of cells in the si-ATB group was lower than that in the control group. Also, lncRNA-ATB knockdown inhibited the invasion ability of human NSCLC cells (p < 0.05). Tumor formation assay data indicate that lncRNA-ATB knockdown significantly repressed the subcutaneous tumor formation ability of NSCLC cells. Furthermore, lncRNA-ATB knockdown in NSCLC cells up-regulated miR-200a, miR-200b and miR-200c.

Conclusion: The expression level of LncRNA-ATB is elevated in carcinoma tissues of NSCLC patients, and its knockdown suppresses the proliferation and invasion of NSCLC cells by up-regulating miR-200s. This finding suggests that it is a potential strategy for the management of NSCLC patients.

Keywords: lncRNA-ATB, Non-small cell lung cancer (NSCLC), Cell proliferation, Cell invasion, miR-200s